Tildrakizumab and omalizumab: An interlocking therapy for autoimmune conditions
Journal: Journal of Clinical Images and Medical Case Reports (Vol.2, No. 4)Publication Date: 2021-08-31
Authors : Laura Diluvio; Chiara Pensa; Arianna Piccolo; Caterina Lanna; Luca Bianchi; Elena Campione;
Page : 1-3
Keywords : Chronic spontaneous urticarial; dual biologic therapy; omalizumab; psoriasis; tildrakizumab;
Abstract
In Western countries the number of individuals suffering from an autoimmune condition is constantly growing and often patients suffering from autoimmune disease are susceptible to developing a second autoimmune disorder. We report a case of an adult female patient affected by psoriasis vulgaris and treated with tildrakizumab, a humanized monoclonal antibody targeting interleukin-23, who later developed chronic spontaneous urticaria and started omalizumab, a humanized antibody to IgE, showing a favorable outcome. We speculate that the two combined therapies have restored the cytokine balance bringing it towards tolerance and remission of the two pathologies. It is conceivable that tildrakizumab may have a synergic action with omalizumab in the treatment of urticaria in patients affected by both psoriasis and urticaria. Our case and the study of the mechanisms of action of the two drugs suggest how the two therapies can act with an interlocking mechanism in achieving the final therapeutic effect.
Other Latest Articles
- Cowden syndrome and Lhermitte - Duclos disease: A case report and review of the literature
- A masked ST-elevation myocardial infarction
- Typical, rare and atypical CT findings in COVID-19 pneumonia: A pictorial review
- Primary oral tuberculosis in an immunocompetent patient
- Intestinal gangrene as the presenting manifestation of acute promyelocytic leukemia
Last modified: 2021-12-10 08:57:32